AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02199379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
Study NCT01928615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - intravenous solution
Description: Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
Study NCT01928615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - subcutaneous solution
Description: Trastuzumab was supplied as a solution for subcutaneous injection.
Study NCT04095923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media game
Description: Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
Study NCT04250207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Placebo solution drops for K-321
Study NCT04278924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-079 placebo-matching SC injection.
Study NCT04278924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.
Study NCT04095923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard self-regulation
Description: Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
Study NCT03115346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aid for repair type for aortic abdominal aneurysms
Study NCT04474600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
Study NCT04474600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
Study NCT03861273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06838435/ fidanacogene elaparvovec
Description: Gene Therapy
Study NCT03788291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg by mouth twice a day starting on day 8 of cycle 1
Study NCT03788291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
Study NCT04217421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
Study NCT04217421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
Study NCT02768805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine
Study NCT02768805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine
Study NCT02768805 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 15 µg/strain of the licensed quadrivalent vaccine
Description: Single dose of the licensed quadrivalent vaccine
Study NCT01021644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise-training
Description: 3 times per week for 6 months
Study NCT01021644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretch exercise
Description: 3 times per week for 6 months
Study NCT01061905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie information
Description: Posting of Calorie information for sugar-sweetened and zero-calorie beverages
Study NCT01061905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Equivalent only
Description: Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
Study NCT01061905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie & Exercise equivalent information
Description: Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
Study NCT00258479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModafinilNicotine Replacement Therapy
Description: A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
Study NCT00258479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ModafinilNicotine Replacement Therapy
Description: A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
Study NCT00258479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: See Modafinil Intervention Description above.
Study NCT00258479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: See Modafinil Intervention Description above.
Study NCT01546571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: POL-103A
Description: POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
Study NCT01546571 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: POL-103A without API
Description: Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
Study NCT01040663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
Study NCT03034382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
Study NCT03034382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
Study NCT03034382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: 10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
Study NCT03034382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
Study NCT03034382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
Study NCT03411811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
Study NCT03411811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
Study NCT04038476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard monitoring + transcutaneous CO2 monitoring
Description: The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
Study NCT04038476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard monitoring
Description: The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
Study NCT04401722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PANCREATICODUDENECTOMY
Description: dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
Study NCT00836069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No drug name provided by Sponsor; drug referenced as PD 0332334
Description: Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
Study NCT00836069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
Study NCT00836069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance, oral tablet, once per day, for 10 weeks.
Study NCT03739411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT03739411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03739411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy for cancer outside of this study.
Study NCT03739411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Undergo chemotherapy for cancer outside of this study.
Study NCT00898274 — intervention group
Intervention type: OTHER
Intervention: immunoenzyme technique
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
Study NCT00898274 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
Study NCT01141140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.
Study NCT01141140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management
Study NCT01141140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS
Description: JUUL 5%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study NCT00196170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF ablation of the cavo-tricuspid isthmus
Description: 8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
Study NCT00196170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo ablation of the cavo-tricuspid isthmus
Description: Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
Study NCT00196170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus
Description: irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
Study NCT00196170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo 6.5mm tip ablation of the cavotricuspid isthmus
Description: cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
Study NCT02727621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
Study NCT02727621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
Study NCT02058914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fructose sweetened beverage
Description: 710 ml per day of a HF-sweetened beverage
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS
Description: JUUL 5%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette
Description: Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco/Nicotine Abstention
Description: No smoking for 6-days in confinement.
Study NCT04107779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand of cigarettes
Description: Continue smoking UB for 6-days in confinement.
Study NCT01904565 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperthermia and Proton Beam
Description: 1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose.
Study NCT04005092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hCPAP versus HFNC
Description: The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
Study NCT01658852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Study NCT01658852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04022434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placedo
Description: Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
Study NCT04022434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
Study NCT04498312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
Study NCT01928615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy for early breast cancer.
Study NCT01500005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby D3 drops
Description: 2000-4000 iu per day
Study NCT02230176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study NCT02230176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA0-Tyr3-Octreotate
Study NCT01974362 — intervention group
Intervention type: DEVICE
Intervention: Dental Implant
Description: Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
Study NCT01974362 — intervention group
Intervention type: DEVICE
Intervention: Monolithic Zirconia (MZ)
Description: rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
Study NCT01974362 — intervention group
Intervention type: DEVICE
Intervention: Zirconia-Feldspathic (PVZ)
Description: restore dental implants with a zirconia suprastructure and feldspathic veneers
Study NCT01974362 — intervention group
Intervention type: DEVICE
Intervention: Monolithic Zirconia (FCMZ)
Description: Full contour full arch zirconia rehabilitation
Study NCT03452150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0316
Description: If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
Study NCT03952637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV9-GLB1
Description: The risks of administering this treatment in a subject with GM1 gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject s immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.